Arcutis Biotherapeutics, Inc. cash flow to debt ratio of -89.77% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Arcutis Biotherapeutics, Inc.'s free cash flow has increased -94.38% from $-112.30M last year to $-6.31M, signaling increasing performance

Arcutis Biotherapeutics, Inc.'s debt to equity ratio is 0.52, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Arcutis Biotherapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.70 last year to 0.52 today, signaling strengthened financials

Arcutis Biotherapeutics, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Arcutis Biotherapeutics, Inc.'s interest coverage ratio of 2.47 indicates that earnings with margin can cover interest payments on company debt

Arcutis Biotherapeutics, Inc.'s profit margin has increased (-108.63%) in the last year from -71.25% to 6.15%, signaling increasing performance

Arcutis Biotherapeutics, Inc.'s short-term assets of $411.23M exceed its short-term liabilities of $129.84M

Arcutis Biotherapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Arcutis Biotherapeutics, Inc.'s return on equity of 15.05%, is higher than 15.00%, indicating good performance

Arcutis Biotherapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Arcutis Biotherapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Arcutis Biotherapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Arcutis Biotherapeutics, Inc. has negative free cash flow, indicating cash burn

Arcutis Biotherapeutics, Inc.'s yearly earnings has increased -88.47% since last year from $-140.04M to $-16.14M, signaling increasing performance

Arcutis Biotherapeutics, Inc.'s yearly revenue has increased 91.34% since last year from $196.54M to $376.07M, signaling increasing performance

ROIC 9.95% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Arcutis Biotherapeutics, Inc.'s 3-year revenue CAGR of 367.27% is positive, indicating growing revenue over the past 3 years

Arcutis Biotherapeutics, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Arcutis Biotherapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Arcutis Biotherapeutics, Inc. has insufficient data to evaluate this check.

Arcutis Biotherapeutics, Inc. has an earnings yield of 0.83%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Arcutis Biotherapeutics, Inc. is overvalued relative to its fair value price of 0.44 based on EBITDA multiple model

Arcutis Biotherapeutics, Inc. has an EV/EBITDA ratio of 1.31Kx, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Arcutis Biotherapeutics, Inc. has insufficient data to evaluate this check.

Arcutis Biotherapeutics, Inc. has a PEG-ratio under 1 which is considered undervalued

Arcutis Biotherapeutics, Inc. has a price-to-book ratio of 15.50x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Arcutis Biotherapeutics, Inc. has a price-to-sales ratio of 7.37x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue